HUTCHMED (China) Limited Sponsored ADR $HCM Shares Sold by M&G PLC

M&G PLC cut its position in shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 21.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,432 shares of the company’s stock after selling 55,185 shares during the period. M&G PLC owned approximately 0.12% of HUTCHMED worth $3,271,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Jane Street Group LLC lifted its holdings in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the last quarter. ABN Amro Investment Solutions acquired a new stake in HUTCHMED during the second quarter worth $962,000. Tema Etfs LLC purchased a new stake in HUTCHMED in the second quarter valued at $641,000. Goldman Sachs Group Inc. grew its holdings in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after purchasing an additional 7,342 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of HUTCHMED by 19.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after purchasing an additional 4,116 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Price Performance

Shares of NASDAQ:HCM opened at $14.87 on Wednesday. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $19.50. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. The firm’s 50-day moving average is $14.44 and its two-hundred day moving average is $15.12.

Wall Street Analysts Forecast Growth

HCM has been the topic of a number of recent analyst reports. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.